Alivexis and Melodia Therapeutics Join Forces to Develop MDI-0151 for Inflammatory Diseases
Shots:
- Alivexis has signed an exclusive license agreement with Melodia Therapeutics to develop, manufacture & commercialize its MDI-0151. Both will use their drug discovery knowledge to generate PoC
- The agreement provides Melodia with exclusive global rights to develop, manufacture & commercialize MDI-0151. Alivexis will receive an aggregate of ~$275M upfront as well as development & sales milestones, plus royalties along with warrants for Melodia’s common shares
- Melodia will begin MDI-0151’s IND-enabling process to conduct a P-I/IIa trial for treating refractory inflammatory diseases caused due to excessive neutrophil activation incl. ANCA-associated vasculitis & other related diseases
Ref: Alivexis | Image: Alivexis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
